3B Blackbio DX Ltd

₹ 759 -0.89%

19 Apr - close price

kilpest.com BSE: 532067

About

3B Blackbio DX (previously known as Kilpest India) is into Crop protection, Public health products and bio-products and is also a supplier to various Govt. organizations, such as FCI (Food Corporation of India), NTPC (National Thermal Power Corporation Limited), Railway, etc. The company is also exporting its products to Bangladesh and Afghanistan.
The company entered into molecular diagnostics with 3B BlackBio BiotechIndia Ltd. ^[1]^[2]

Key Points

3B BlackBio Biotech India Limited (Subsidiary)^[1]
Incorporated in 2011, “3B BlackBio Biotech India Limited”, a subsidiary of Kilpest India Limited, is engaged in Design, Development Manufacturing and Commercialization of qPCR tests, Rapid tests, NGS based Molecular Diagnostic Kits and Extraction Kits. The company has the largest range of CE-IVD products in the molecular diagnostics segment.
Brands: TRUPCR, TRURAPID, truNGS, TRUPCR Europe.

Website BSE

Market Cap ₹ 570 Cr.
Current Price ₹ 759
High / Low ₹ 924 / 390
Stock P/E 20.5
Book Value ₹ 278
Dividend Yield 0.33 %
ROCE 19.1 %
ROE 16.0 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Company has delivered good profit growth of 49.9% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 44.5%
Promoter holding has increased by 2.86% over last quarter.

Cons

Company has high debtors of 200 days.
Working capital days have increased from 161 days to 248 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
	42.69	18.88	32.67	15.22	14.36	18.40	11.69	17.31	14.73	18.11	14.28	19.18	17.67
	17.72	10.37	14.46	9.22	7.39	12.48	6.51	8.13	7.42	10.65	7.84	11.39	8.80
Operating Profit	24.97	8.51	18.21	6.00	6.97	5.92	5.18	9.18	7.31	7.46	6.44	7.79	8.87
OPM %	58.49%	45.07%	55.74%	39.42%	48.54%	32.17%	44.31%	53.03%	49.63%	41.19%	45.10%	40.62%	50.20%
	1.58	1.19	1.55	1.94	1.54	1.87	1.24	1.96	2.88	1.15	2.96	2.75	2.63
Interest	0.03	0.04	0.03	0.06	0.03	-0.02	0.03	0.07	0.05	0.04	0.02	0.04	0.03
Depreciation	0.23	0.11	0.15	0.18	0.17	0.17	0.17	0.24	0.25	0.21	0.19	0.24	0.32
Profit before tax	26.29	9.55	19.58	7.70	8.31	7.64	6.22	10.83	9.89	8.36	9.19	10.26	11.15
Tax %	25.14%	25.55%	23.70%	23.64%	21.06%	36.91%	24.12%	23.27%	22.04%	37.80%	21.55%	26.02%	23.68%
	19.67	7.10	14.94	5.88	6.56	4.82	4.72	8.31	7.72	5.20	7.21	7.58	8.51
EPS in Rs	22.98	8.24	17.53	6.85	7.66	5.53	5.39	11.20	8.96	6.01	9.71	10.46	11.61
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
	21	20	22	19	17	16	23	23	29	227	81	62	69
	20	19	21	18	16	14	18	16	20	77	44	33	39
Operating Profit	1	1	1	1	2	3	5	7	9	150	37	29	31
OPM %	5%	6%	6%	7%	9%	16%	23%	31%	32%	66%	46%	47%	44%
	0	0	0	0	0	0	0	1	2	3	7	7	9
Interest	1	1	1	1	1	1	1	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	1	1	1	1	1	1
Profit before tax	0	1	0	0	0	1	5	7	10	152	43	35	39
Tax %	104%	34%	14%	23%	23%	19%	24%	25%	23%	25%	26%	27%
	-0	0	0	0	0	1	3	5	8	114	32	26	28
EPS in Rs	-0.02	0.62	0.59	0.36	0.51	1.76	5.35	8.18	10.24	151.66	42.89	34.55	37.79
Dividend Payout %	0%	0%	0%	0%	0%	17%	9%	6%	7%	6%	24%	7%

Compounded Sales Growth
10 Years:	12%
5 Years:	22%
3 Years:	29%
TTM:	11%

Compounded Profit Growth
10 Years:	52%
5 Years:	50%
3 Years:	50%
TTM:	20%

Stock Price CAGR
10 Years:	60%
5 Years:	55%
3 Years:	32%
1 Year:	74%

Return on Equity
10 Years:	39%
5 Years:	43%
3 Years:	44%
Last Year:	16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	6	6	6	6	6	6	6	6	7	7	7	7	9
Reserves	3	3	4	4	4	5	12	16	25	125	146	164	200
	6	6	7	8	8	9	6	6	4	2	3	2	1
	7	7	7	7	6	6	6	8	9	59	37	41	15
Total Liabilities	22	23	24	25	24	26	30	36	45	194	192	214	225
	4	4	4	4	3	3	4	4	4	5	7	8	8
CWIP	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0	1	59	93	92	96
	18	19	20	21	21	22	26	32	40	130	93	114	122
Total Assets	22	23	24	25	24	26	30	36	45	194	192	214	225

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
	0	-1	0	0	1	1	2	4	7	98	37	23
	-1	0	-0	-0	-0	-0	-1	-1	-1	-70	-28	12
	1	-0	0	-0	-1	-0	0	-1	1	-2	-15	-5
Net Cash Flow	1	-1	0	-0	0	0	1	2	7	26	-6	30

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	180	220	213	262	283	321	259	290	252	56	136	200
Inventory Days	109	149	120	145	143	175
Days Payable	165	220	189	218	203	186
Cash Conversion Cycle	124	149	144	188	223	310	259	290	252	56	136	200
Working Capital Days	167	214	218	274	312	377	308	351	302	67	169	248
ROCE %	7%	8%	7%	7%	7%	13%	24%	28%	31%	162%	27%	19%

Shareholding Pattern

Numbers in percentages

	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
	38.35%	38.35%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	38.43%	41.29%
	1.47%	0.54%	1.23%	1.64%	1.64%	1.64%	2.11%	2.54%	3.06%	3.16%	3.38%	2.97%
	0.09%	0.08%	0.08%	0.08%	0.08%	0.00%	0.00%	0.00%	0.00%	0.82%	1.18%	1.89%
	60.09%	61.03%	60.26%	59.85%	59.85%	59.94%	59.47%	59.02%	58.50%	57.60%	56.99%	53.85%
No. of Shareholders	10,541	16,251	16,756	16,468	16,316	15,415	13,798	13,136	12,416	10,513	10,088	9,753

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	43.42%	43.42%	43.87%	38.19%	38.35%	38.43%	38.43%	41.29%
	0.00%	0.00%	0.00%	0.00%	1.10%	1.64%	2.54%	2.97%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.08%	0.00%	1.89%
	56.58%	56.58%	56.13%	61.81%	60.55%	59.85%	59.02%	53.85%
No. of Shareholders	1,786	2,009	2,352	2,697	9,772	16,468	13,136	9,753

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Feb 2024

Transcript

Notes
PPT
Nov 2023

Transcript

Notes
PPT
Aug 2023

Transcript

Notes
PPT
May 2023

Transcript

Notes
PPT
Feb 2023

Transcript

Notes
PPT
Nov 2022

Transcript

Notes
PPT
Sep 2022

Transcript

Notes
PPT
Aug 2022

Transcript

Notes
PPT
May 2022

Transcript

Notes
PPT
Feb 2022

Transcript

Notes
PPT
Nov 2021

Transcript

Notes
PPT
Sep 2021

Transcript

Notes
PPT
Jul 2021

Transcript

Notes
PPT
Jun 2021

Transcript

Notes
PPT
Feb 2021

Transcript

Notes
PPT
Feb 2021

Transcript

Notes
PPT
Nov 2020

Transcript

Notes
PPT
Sep 2020

Transcript

Notes
PPT
Jul 2020

Transcript

Notes
PPT
Jun 2020

Transcript

Notes
PPT
Feb 2020

Transcript

Notes
PPT
Nov 2019

Transcript

Notes
PPT
Jul 2019

Transcript

Notes
PPT
May 2019

Transcript

Notes
PPT
Jan 2019

Transcript

Notes
PPT
Nov 2018

Transcript

Notes
PPT
Aug 2018

Transcript

Notes
PPT
May 2018

Transcript

Notes
PPT
Feb 2018

Transcript

Notes
PPT
Nov 2017

Transcript

Notes
PPT
Jul 2017

Transcript

Notes
PPT
Feb 2017

Transcript

Notes
PPT